News
Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...
The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic ...
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback